Bristol-Myers Squibb (BMY) Tops Q2 EPS by 43c, provides guidance

Bristol-Myers Squibb (NYSE: BMY) reported Q2 EPS of $2.07, $0.43 better than the analyst estimate of $1.64. Revenue for the quarter came in at $12.2 billion versus the consensus estimate of $11.52 billion.

GUIDANCE:

Bristol-Myers Squibb sees Q3 2024 EPS of $0.60-$0.90, versus the consensus of $0.51.

Revenue: Upper end of low single- digit range

For earnings history and earnings-related data on Bristol-Myers Squibb (BMY) click here.

You May Also Be Interested In

• Crude Inventory Fell 3.8 Million Barrels Last Week, Says EIA
• TD Cowen on TransMedics Amid 6% Gain: 'transplant logistics business experienced ~18.5% y/y growth'
• Nebius Group (NBIS) call put ratio 1.6 calls to 1 put as share price down 12.9%